Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by Stackinstockson Dec 21, 2017 3:50pm

79 Views

Post# 27209156

RE:RE:NF & NHS

Right which is what I have been saying. No matter how much proof I supply people deny it. This is the 6th official document that has referenced the situation here.

If this does not prove thta NF does not own Langley I am not sure what will!

Bullboard Posts

Micron Technology expands Crucial portfolio at CES 2025